

the nucleic acid of claim 2[, 3 or 4] under conditions whereby the Ese1 protein is expressed and isolating the Ese1 protein therefrom.

28. (Amended) A recombinant vector comprising the isolated nucleic acid of claim 20 [any of claims 20 to 26].

38. (Amended) A process for recombinantly producing murine Ese2 protein comprising culturing a host cell comprising a recombinant vector comprising the nucleic acid of claim 20[, 21 or 22] under conditions whereby the Ese2 protein is expressed and isolating the Ese2 protein therefrom.

42. (Amended) The method of claim 40[or 41], wherein said disorder is selected from the group consisting of cancer, abnormal cell division, abnormal cell migration, viral infection, abnormal receptor signalling, abnormal tissue development and abnormal synaptic transmission disorders.

Please add the following new claims.

50. A recombinant vector comprising the isolated nucleic acid of claim 7.

51. A host cell comprising the recombinant vector of claim 50.

52. A process for recombinantly producing murine Ese1 protein comprising culturing a host cell comprising a recombinant vector comprising the nucleic acid of claim 3 under conditions whereby the Ese1 protein is expressed and isolating the Ese1 protein therefrom.

53. A process for recombinantly producing murine Ese1 protein comprising culturing a host cell comprising a recombinant vector comprising the nucleic acid of claim 4 under conditions whereby the Ese1 protein is expressed and isolating the Ese1 protein therefrom.

54. A recombinant vector comprising the isolated nucleic acid of claim 26.

55. A host cell comprising the recombinant vector of claim 54.

56. A process for recombinantly producing murine Ese2 protein comprising culturing a host cell comprising a recombinant vector comprising the nucleic acid of claim 21 under conditions whereby the Ese2 protein is expressed and isolating the Ese2 protein therefrom.

57. A process for recombinantly producing murine Ese2 protein comprising culturing a host cell comprising a recombinant vector comprising the nucleic acid of claim 22 under conditions whereby the Ese2 protein is expressed and isolating the Ese2 protein therefrom.

58. The method of claim 41, wherein said disorder is selected from the group consisting of cancer, abnormal cell division, abnormal cell migration, viral infection, abnormal receptor signalling, abnormal tissue development and abnormal synaptic transmission disorders.

Remarks

Claims 9, 19, 28, 38 and 42 have been amended, and new Claims 50-58 added, to remove multiple dependencies from the claims. It is submitted that this application is now in condition for substantive examination, which action is respectfully requested.


Respectfully submitted,


Karen A. Magri
Registration No. 41,965

Myers Bigel Sibley & Sajovec
Post Office Box 37428
Raleigh, NC 27627
Tel. (919) 854-1400
Fax (919) 854-1401

"Express Mail" mailing label number EL682671390US
Date of Deposit: October 27, 2000

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Box PCT, Commissioner for Patents, Washington, DC 20231.


Marjorie J. Pfeiffer
Date of Signature: October 27, 2000